Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Surekha M. Zingde is active.

Publication


Featured researches published by Surekha M. Zingde.


Bioinformation | 2011

Database and interaction network of genes involved in oral cancer: Version II

Nikhil Sureshkumar Gadewal; Surekha M. Zingde

The oral cancer gene database has been compiled to enable fast retrieval of updated information and role of the genes implicated in oral cancer. The first version of the database with 242 genes was published in Online Journal of Bioinformatics 8(1), 41-44, 2007. In the second version, the database has been enlarged to include 374 genes by adding 132 gene entries. The architecture and format of the database is similar to the earlier version, and includes updated information and external hyperlinks for all the genes. The functional gene interaction network for important biological processes and molecular functions has been rebuilt based on 374 genes using ‘String 8.3’. The database is freely available at http://www.actrec.gov.in/OCDB/index.htm and provides the scientist information and external links for the genes involved in oral cancer, interactions between them, and their role in the biology of oral cancer along with clinical relevance.


Cancer Biomarkers | 2009

Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response.

Sanjeev Shukla; Atul Pranay; Anil D'Cruz; Pankaj Chaturvedi; Shubhada Kane; Surekha M. Zingde

Autoantibody response to tumor antigens has been widely used to identify novel tumor markers for different cancers, including that of the head and neck. The oral cavity, which is in the head and neck region, comprises of many sub sites with distinct biologies and incidence of cancer of each sub site of the oral cavity is different. It is anticipated therefore that each sub site of the oral cavity may elicit a differential autoantibody response. This report evaluates the autoantibody response in 15 patients with cancer of gingivo-buccal complex and in 15 patients with cancer of tongue using Immunoproteomics, and shows that the autoantibody response to alpha-enolase, HSP 70, peroxiredoxin-VI, annexin II, pyruvate kinase, alpha-tubulin, beta-tubulin, ATP synthase, triose phosphate isomerase and aldose reductase seen in patients with cancer of gingivo-buccal complex is absent in patients with cancer of tongue. This suggests that cancer of these sub sites should be studied separately because of their different biology and emerging site specific molecular signatures including autoantibody responses to ensure unambiguous clinical interpretations.


Proteomics Clinical Applications | 2009

Proteomic profiling of cancer of the gingivo-buccal complex: Identification of new differentially expressed markers

Rukmini B. Govekar; Anil D'Cruz; K. Alok Pathak; Jai Prakash Agarwal; Ketayun A. Dinshaw; Roshan F. Chinoy; Nikhil Sureshkumar Gadewal; Sadhana Kannan; Ravi Sirdeshmukh; Curam Sreenivasacharlu Sundaram; Siddhi A. Malgundkar; Shubhada Kane; Surekha M. Zingde

Tobacco‐related oral cancer is the most common cancer among Indian males, gingivo‐buccal complex (GBC) being the most affected subsite due to the habit of chewing tobacco. Proteins from the lysates of microdissected normal and transformed epithelium from clinically well‐characterized tissue samples of the GBC were separated by two‐dimensional gel electrophoresis to identify differentially expressed proteins. Eleven protein spots showed differential expression, which could withstand the stringency of statistical evaluation. The observations were confirmed with additional tissues. Nine of these differentiators were identified by MS as lactate dehydrogenase B, α‐enolase, prohibitin, cathepsin D, apolipoprotein A‐I, tumor protein translationally controlled‐1, an SFN family protein, 14‐3‐3σ and tropomyosin. Cluster analysis indicated that these proteins, as a coexpressed set, could distinguish normal and transformed epithelium. Functionally, these differentiator molecules are relevant to the pathways and processes that have been previously implicated in oral carcinogenesis and could therefore be investigated further as a panel of markers for management of cancer of the GBC.


Journal of Proteomics | 2012

Keratins in oral cancer: necessity of mass spectrometry for validation of antibody based identifications.

Amit Fulzele; Siddhi A. Malgundkar; Rukmini B. Govekar; Anil D'Cruz; Pankaj Chaturvedi; Asawari Patil; Shubhada Kane; Surekha M. Zingde

Keratins are intermediate filament family proteins which are predominantly expressed in the epithelial cells. Most of the studies which evaluate the status of keratins in clinical samples of the oral cavity are based on the identification of their presence and localization by immunohistochemistry using monoclonal antibodies. It is very well known that many monoclonal/polyclonal antibodies show cross-reactivity with the other closely related or non-related proteins. This cross-reactivity might be the result of epitope similarity, but it is not always necessary. Therefore studies done with only antibody based techniques can mislead interpretation unless they are validated with additional techniques like mass-spectrometry. In this investigation we have evaluated the status of keratin 18 in cancer of buccal mucosa using 1DE, 2DE and western blotting with monoclonal antibody to keratin 18. The patterns emerging showed aberrant as well as differential expression of K18 in adjacent normal versus tumor tissue samples of buccal mucosa. Mass spectrometry analysis of the immunodetected spots however revealed that it is keratin 13. Thus this study emphasizes the necessity of validation of antibody based findings when dealing with proteins of a large family having similarity/homology in amino acid sequence.


Journal of Proteomics | 2013

Proteomic profile of keratins in cancer of the gingivo buccal complex: consolidating insights for clinical applications.

Amit Fulzele; Siddhi A. Malgundkar; Rukmini B. Govekar; Asawari Patil; Shubhada Kane; Pankaj Chaturvedi; Anil D'Cruz; Surekha M. Zingde

UNLABELLEDnKeratins play a major role in several cellular functions. Each tissue type expresses a specific set of keratins. The immense potential of keratins as diagnostic and prognostic markers for different cancers is emerging. Oral cancer is the fifteenth most common cancer worldwide. However, comprehensive information on the profile of keratins in the oral cavity is not available. Several independent reports have identified keratins using antibody based techniques which have pitfalls due to the cross reactivity of the antibodies to this set of very homologous proteins. A few recent proteomic studies have reported the identification of keratins in head and neck cancer. Majority of the studies have used tissues from the head and neck region without specifying subsites. This study reports the analysis of enriched preparations of keratins from cancer of the gingivo buccal complex (GBC) using MS, 2DE, WB, silver staining of 2DE gels and IHC. Our study reveals the absence of K4 and K13 and presence of K14, K16, and K17, in cancers of the GBC and combination of these expression patterns in the cut margins. This report also shows that K13 is glycosylated. This well characterized profile of keratins may have potential to be used in clinics.nnnBIOLOGICAL SIGNIFICANCEnIn recent years the immense potential of keratins as diagnostic and prognostic markers for different cancers is emerging. However, comprehensive information on the profile of keratins in the oral cavity is not available. Several independent reports have identified keratins using only antibody based techniques which have pitfalls due to the cross reactivity of the antibodies to this set of very homologous proteins. This study reports the analysis of enriched preparations of keratins from a subsite of the oral cavity, the gingivo buccal complex (GBC) using mass spectrometry, 2DE, western blotting, silver staining of 2DE gels and IHC. The proteomic analysis shows the absence of K4 and K13 and presence of K14, K16, and K17 in cancers of the GBC and combination of these expression patterns in the cut margins. This well characterized profile of keratins from the gingivo buccal complex provides defined markers which may have potential to be used in the clinics.


Anemia | 2012

Reduced PKC α Activity Induces Senescent Phenotype in Erythrocytes

Rukmini B. Govekar; Poonam Kawle; Advani Sh; Surekha M. Zingde

The molecular mechanism mediating expression of senescent cell antigen-aggregated or cleaved band 3 and externalized phosphatidylserine (PS) on the surface of aged erythrocytes and their premature expression in certain anemias is not completely elucidated. The erythrocytes with these surface modifications undergo macrophage-mediated phagocytosis. In this study, the role of protein kinase C (PKC) isoforms in the expression of these surface modifications was investigated. Inhibition of PKC α by 30u2009μM rottlerin (R30) and 2.3u2009nM Gö 6976 caused expression of both the senescent cell marker-externalized PS measured by FACS analysis and aggregated band 3 detected by western blotting. In contrast to this observation, but in keeping with literature, PKC activation by phorbol-12-myristate-13-acetate (PMA) also led to the expression of senescence markers. We explain this antithesis by demonstrating that PMA-treated cells show reduction in the activity of PKC α, thereby simulating inhibition. The reduction in PKC α activity may be attributed to the known downregulation of PMA-activated PKC α, caused by its membrane translocation and proteolysis. We demonstrate membrane translocation of PKC α in PMA-treated cells to substantiate this inference. Thus loss of PKC α activity either by inhibition or downregulation can cause surface modifications which can trigger erythrophagocytosis.


Proteomics Clinical Applications | 2013

Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivo-buccal complex using immunoproteomics

Atul Pranay; Sanjeev Shukla; Sadhana Kannan; Siddhi A. Malgundkar; Rukmini B. Govekar; Asawari Patil; Shubhada Kane; Pankaj Chaturvedi; Anil D'Cruz; Surekha M. Zingde

Studies from our laboratory have reported 14 tumor antigens that elicit an autoantibody response in patients with cancer of the gingivobuccal complex (GBC) In this study, utility of the autoantibody response has been evaluated for prognosis of cancer of the GBC.


Anemia | 2012

Eryptotic Phenotype in Chronic Myeloid Leukemia: Contribution of Neutrophilic Cathepsin G

Rukmini B. Govekar; Poonam Kawle; Renjan Thomas; Advani Sh; Sheena Pv; Surekha M. Zingde

In pathological conditions with concurrent neutrophilia, modifications of erythrocyte membrane proteins are reported. In chronic myeloid leukemia (CML), a myeloproliferative disease wherein neutrophilia is accompanied by enhanced erythrophagocytosis, we report for the first time excessive cleavage of erythrocyte band 3. Distinct fragments of band 3 serve as senescent cell antigens leading to erythrophagocytosis. Using immunoproteomics, we report the identification of immunogenic 43u2009kDa fragment of band 3 in 68% of CML samples compared to their detection in only 38% of healthy individuals. Thus, excessive fragmentation of band 3 in CML, detected in our study, corroborated with the eryptotic phenotype. We demonstrate the role of neutrophilic cathepsin G, detected as an immunogen on erythrocyte membrane, in band 3 cleavage. Cathepsin G from serum adsorbs to the erythrocyte membrane to mediate cleavage of band 3 and therefore contribute to the eryptotic phenotype in CML.


International Journal of Human Genetics | 2007

Cancer Proteomics: How Far are We from the Clinics?

Rukmini B. Govekar; Surekha M. Zingde

Abstract Cancer, in spite of several years of research and consequent improvements in clinical management of the disease, shows limited decline in the associated patient mortality and morbidity. In order to achieve better and early diagnosis, design appropriate treatment strategies and precise prognostication, molecular markers which could subclassify tumors are being assessed to complement TNM classification. Plethora of information is spilling out from the recent high-throughput technologies for global profiling. Time has come to assess the technologies, study designs and data processing to obtain information which is clinically relevant. This review analyses the state of the art in Cancer Proteomics and the issues, which need to be addressed to move the technology from the bench to the bedside.


Journal of Proteomics | 2015

Has Proteomics come of age in India

Surekha M. Zingde

Collaboration


Dive into the Surekha M. Zingde's collaboration.

Top Co-Authors

Avatar

Rukmini B. Govekar

Council of Scientific and Industrial Research

View shared research outputs
Top Co-Authors

Avatar

Anil D'Cruz

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nikhil Sureshkumar Gadewal

Council of Scientific and Industrial Research

View shared research outputs
Top Co-Authors

Avatar

Ravi Sirdeshmukh

Centre for Cellular and Molecular Biology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Advani Sh

Tata Memorial Hospital

View shared research outputs
Top Co-Authors

Avatar

Curam Sreenivasacharlu Sundaram

Centre for Cellular and Molecular Biology

View shared research outputs
Researchain Logo
Decentralizing Knowledge